Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction

Login or register to view PDF.
Creative Commons Licence
Received date
13 May 2020
Accepted date
13 May 2020
European Cardiology Review 2020;15:e32.
Open access
This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Aims: To describe the clinical characteristics, safety and tolerability profile, and discontinuation causes of sacubitril/valsartan (SV) treatment in patients attending an outpatient heart failure clinic.

Design and methods: We collected data from 119 consecutive patients between May and November 2018. Variables were collected baseline and post-SV titration period.

Results: 64 patients (53.8%) were treated with SV. Mean age was 63 ± 10 years, 76.6% men. Mean left ventricular ejection fraction 28 ± 6%; 39% had ischaemic aetiology; and 67% were New York Heart Association class II. Median NT-proBNP 1,176 pg/ml (IQR 364–3,945). Mean glomerular filtration rate (GFR) was 71.7 ± 20.6 ml/min and potassium 4.4 ± 0.4 mEq/l. The majority (84%) of patients were treated with angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers, 95% with beta-blockers and 86% with mineralocorticoid receptor antagonists. Median titration time was 6.5 weeks (IQR 3–13.2). Target dose was achieved in 23 patients (40%). Dose reduction was needed in 24 patients (37.5%) and 10 (15.6%) discontinued therapy. Causes for therapy discontinuation were hypotension, defined as systolic blood pressure (SBP) <90 mmHg (n=4, 6.2%), potassium >5.5 mEq/l (n=2, 3.1%) and diarrhoea (n=1, 1.6%). Patients who presented with at least one adverse event were older, with lower SBP and GFR (all p<0.05). In a multivariate analysis, lower SBP (OR 0.94, 95% CI [0.90–0.99]) was the only variable independently associated with adverse events.

Conclusion: In our cohort, SV has an acceptable tolerability profile. The proportion of patients who achieved target dose was lower than the reported in clinical trials, despite a longer titration time. Hypotension represents the main cause of reduction or discontinuation of SV.